Study of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Inclusion Criteria

• Female participants.
• At least 15 years old.
• Weigh more than 35 kg (about 77 pounds).
• Diagnosed with specific types of cervical cancer (stages IIIC to IVA) with lymph node involvement.
• Initial cancer staging done within 42 days before starting chemotherapy and radiation.
• Provide a tumor sample to check for PD-L1 expression.
• Cancer has not worsened after chemotherapy and radiation, and no other curative treatments are available.
• Good overall health with a performance status of 0 or 1.
• Healthy organ and bone marrow function.
• Able to give informed consent.

Exclusion Criteria

• Diagnosed with small cell or mucinous adenocarcinoma of the cervix.
• Cancer has spread to other parts of the body.
• Planning to undergo fertility-sparing treatment.
• History of organ transplant.
• Have active or past autoimmune or inflammatory disorders.
• Have uncontrolled illnesses.
• Have had another cancer unless treated and inactive for at least 2 years, or certain skin cancers or carcinoma in situ.
• Have unresolved side effects from previous treatment, except for permanent side effects not expected to worsen.
• Have or had certain types of fistulas.
• History of severe allergic reactions to biological therapies or vaccines.
• Use of immunosuppressive medication within 14 days before starting the study, with some exceptions.
• Have had a hysterectomy or will have one as part of initial cancer treatment.
• Have had other treatments for cervical cancer besides chemotherapy and radiation.
• Major surgery within 4 weeks before starting the study or still recovering from surgery.
• Have received immune therapy before the study.
• Have received a live vaccine within 30 days before starting the study.
• Known allergy or sensitivity to the study drug or its ingredients.